GlassScriptPhysician profile
Robert C Madonna
NPI 1013931088
$14,491.83
in general payments reported to CMS, 2019-2025
54 companies · $2,728 in 2025
The $2,728 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $1,503 · 2021: $2,002 · 2022: $2,010 · 2023: $2,264 · 2024: $2,398 · 2025: $2,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,389.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,290.99 | 2019-2025 | |
| Novo Nordisk INC | $1,446.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,228.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $991.59 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.71 | 2019-2025 | Jardiance, Spiriva Respimat |
| Pfizer INC. | $624.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $604.20 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $532.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $529.17 | 2020-2025 | Airsupra, Farxiga, Fasenra |
| Amgen INC. | $495.03 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $463.06 | 2019-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $431.89 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Merck Sharp & Dohme LLC | $376.26 | 2019-2023 | Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $363.51 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $351.71 | 2023-2025 | Rexulti |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $228.50 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.52 | 2019-2024 | Xifaxan |
| Neurocrine Biosciences, INC. | $183.65 | 2023-2025 | Ingrezza |
| Amarin Pharma, INC. | $179.25 | 2019-2021 | |
| Abbott Laboratories | $177.43 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Kaleo, INC. | $160.76 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $139.89 | 2019-2024 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $138.93 | 2023-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $125.04 | 2021 | |
| Almatica Pharma LLC | $118.14 | 2022-2025 | Loreev Xr, Teriparatide |
| Sanofi-Aventis U.S. LLC | $116.54 | 2020-2022 | |
| Shield Therapeutics INC | $103.82 | 2024-2025 | |
| Optinose US, INC. | $88.60 | 2022-2025 | |
| Celgene Corporation | $74.34 | 2019 | |
| Exact Sciences Corporation | $74.29 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $74.27 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $70.77 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.63 | 2025 | Caplyta |
| Dexcom, INC. | $58.21 | 2022-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $55.72 | 2021-2025 | Unithroid |
| Verona Pharma, INC. | $51.67 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $49.32 | 2022-2024 | Gvoke Hypopen |
| Tolmar, INC. | $48.43 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.33 | 2022 | |
| Horizon Therapeutics Plc | $39.86 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $29.83 | 2019-2022 | |
| Lundbeck LLC | $29.45 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $28.67 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $24.29 | 2025 | |
| Eisai INC. | $22.68 | 2020 | |
| Ibsa Pharma INC. | $19.87 | 2022 | |
| Eyevance Pharmaceuticals LLC | $19.65 | 2021 | |
| Verity Pharmaceuticals INC. | $18.82 | 2024 | Tlando |
| Acella Pharmaceuticals, LLC | $17.39 | 2024 | NP Thyroid 60 |
| Arbor Pharmaceuticals, INC. | $15.89 | 2022 | |
| Genentech USA, INC. | $14.85 | 2020 | |
| Impel Pharmaceuticals INC. | $14.29 | 2022 | |
| Aytu Biopharma, INC. | $14.16 | 2019 | |
| Clarus Therapeutics INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Madonna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.